Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rilzabrutinib in adult participants with Graves’ disease
2025-521023-75-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of rilzabrutinib in Graves' disease and Graves Orbitopathy (GO), sponsored by Sanofi. Primary endpoint: Percent change from baseline in FT4 levels. Planned start Oct 2025; status: authorised.
02
Drugs
rilzabrutinib
03
Conditions
Graves' diseaseGraves Orbitopathy (GO)
Beyond the preview
Go deeper on 2025-521023-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521023-75-00.